Trial Profile
A Single Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3006072 in Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2019
Price :
$35
*
At a glance
- Drugs LY 3006072 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 08 Apr 2014 New trial record